GSK and Theravance receive FDA approval for asthma drug Breo Ellipta

GlaxoSmithKline (GSK) and Theravance have received approval from the US Food and Drug Administration (FDA) for the Breo Ellipta (fluticasone furoate/vilanterol [FF/VI]) as the once-daily treatment for asthma patients aged 18 years and older.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news